fast Punktlandung auf dem Bollinger und dreht nach oben
Aber mal abwarten
Aber mal abwarten
Anzeige
Meldung des Tages: US-Kupferkrise – warum Projekte in Nevada plötzlich systemrelevant werden könnten
Neuester,
zuletzt geles. Beitrag
Antworten | Börsen-Forum Übersicht
Zurück
Weiter
... 309 310 312 313 ...
Antworten | Börsen-Forum Übersicht
Zurück
Weiter ... 309 310 312 313 ...
Ariad Pharma on the Top
Werbung
Passende Knock-Outs auf DAX
| Strategie | Hebel | |||
| Steigender DAX-Kurs | 5,00 | 10,00 | 15,00 | |
| Fallender DAX-Kurs | 5,00 | 10,00 | 15,00 | |
Den Basisprospekt sowie die Endgültigen Bedingungen finden Sie jeweils hier: DE000VG93X73
, DE000VK2CUW4
, DE000VH9H4E3
, DE000VH4ATM2
, DE000VJ0JNZ4
, DE000VG8DT04
.Bitte informieren Sie sich vor Erwerb ausführlich über Funktionsweise und Risiken. Bitte beachten Sie auch die weiteren Hinweise zu dieser Werbung.
Beiträge:
9.312
Zugriffe: 1.515.152 / Heute: 132
Zugriffe: 1.515.152 / Heute: 132
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi IBEX 35 Doble Apalancado Diario (2x) UCITS ETF Acc
Perf. 12M: +121,30%
Amundi MSCI Greece UCITS ETF Dist
Perf. 12M: +58,29%
Amundi IBEX 35 UCITS ETF Acc
Perf. 12M: +54,03%
Amundi IBEX 35 UCITS ETF Dist
Perf. 12M: +53,36%
übel aus...der fall unter die 6$ marke könnte weiteres downpotenzial freisetzen....ich würde zunächst nicht investieren und auch nicht halten.
naja dreht zumindestens mal wieder rein...
schlechte Aktie . Heute kaufen , morgen fett im minus.Absolutes Schrottpapier.
Möglicherweise könnte tatsächlich ein Zusammenhang zur EMA Entscheidung bestehen. Da versuchen die Shorties unsichere Anleger rauszudrängen um günstig einkaufen zu können... Die EMA hat bisher immer plausibel zugunsten Ariad´s Iclusig entschieden, auch unter Berücksichtigung einer veränderten Einnahmeempfehlung. Die Veröffentlichung neuer Sicherheitsdaten betreffend Iclusig auf dem ASCO in Chicago könnten ein positives Votum unterstützen. Also: locker bleiben....
Wann ist denn die EMA-entscheidung ??
The review of Iclusig under the Article 20 procedure by the Pharmacovigilance Risk Assessment Committee (PRAC) is ongoing in Europe. This procedure is aimed at obtaining a better understanding of the adverse events observed with Iclusig and proposing potential ways to further improve its benefit/risk profile. We have received the PRAC list of preliminary outstanding issues being discussed at its ongoing meeting this week. We expect to receive the final list of follow-up questions from the PRAC at the conclusion of this meeting and anticipate a recommendation by the PRAC and an opinion by the Committee for Medicinal Products for Human Use in July, two months later than originally anticipated.
Source: investor.ariad.com/...ewsArticle&ID=1928071&highlight=
ARIAD Pharmaceuticals, 07MAY2014
Source: investor.ariad.com/...ewsArticle&ID=1928071&highlight=
ARIAD Pharmaceuticals, 07MAY2014
Bis ende July ist ja nicht mehr lange.
2 Wochen davon häng ich eh in Spanien rum
Thx
2 Wochen davon häng ich eh in Spanien rum
Thx
Ist das die Entscheidung die den Kurs 2013 hat fallen lassen??
heutige Abstrurz hat nicht direkt was it Ariad zu tun sondern der Allgemein Markt hat heute einen Raben Schwarzen Tag erwicht.Grund dafür zu einem haben wir Sommerloch anfang viele Urlaub etc das sieht man heute Intray besonders bei den Indiz die alle samt fett - Haben.Ariad hat dies genutzt um ein Gap bei 5,80 zu schliessen.Somit wäre nur noch ein Gap was in betracht werden müsste das bei rund 5,55 das andere bei rund 2,80 dürfte nicht mehr relevant sein.RSI stark überverkauft.Es wird sich zeigen was draus wird jetzt ohne News usw werden wir wieder in die seitswäts line ziehen rauf runter zwischen 5,55 und 6,55
Wo hier alle so traurig und aggro sind: ich sag es war ein Dipp vor positiven EMA News - viel Spaß beim Fußball!!;-))
... noch dieser Kursverlauf bei der hohen Shortrate
Die haben ja so ein leichtes Spiel wie wir gegen Brazilien :)
Wann dreht diese Kackaktie endlich mal wieder nach oben ???
Die haben ja so ein leichtes Spiel wie wir gegen Brazilien :)
Wann dreht diese Kackaktie endlich mal wieder nach oben ???
Trauer spiel ja aber man muss ja auch nicht investier sein ;-).Ich würde garnicht mehr jeden tag rein sehen sondern laufen lassen wer absichern will Stopp setzen und fertig
Gelgenheit zum nachkaufen.
Deepest Down max 5.55$
So dann, werte Kurspropheten
Deepest Down max 5.55$
So dann, werte Kurspropheten
(Verkleinert auf 72%) 
Unser baldiger Pennystock.
Es gibt keinen Tag mehr mit Plus?! :D. Naja stoploss vergessen, soll alles hin sein ;)
Es gibt keinen Tag mehr mit Plus?! :D. Naja stoploss vergessen, soll alles hin sein ;)
www.marketvolume.com/stocks/...RIA&t=ariad-pharmaceuticals
Demnach ist ARIAD überverkauft .
www.broker-test.de/forex-broker/...n/ueberkauft-ueberverkauft/
Demnach ist ARIAD überverkauft .
www.broker-test.de/forex-broker/...n/ueberkauft-ueberverkauft/
grün ;-) naja habe gerade auch erst gesehen bzw rein geschaut wenn ich es heute mittag gemacht hätte wäre der tag so :-( jetzt ist er so ;-) hihi
Ein Auszug eines interessanten Interview mit Dr. Reni Benjamin (managing director and director of research, H.C. Wainwright & Co).
…
TLSR: Could you mention another name?
RB: Sure. Ariad Pharmaceuticals Inc. (ARIA:NASDAQ) is a turnaround story as well. Last year the company ran into a significant snag. Ariad had the distinct pleasure of not only successfully getting Iclusig (ponatinib) approved in mid-December 2012, a full three months ahead of its Prescription Drug User Fee Act (PDUFA) date, but it also achieved regulatory approval both in the U.S. and in Europe for the drug. Iclusig was approved for third-line use in chronic myelogenous leukemia (CML). Ariad was running a head-to-head Phase 3 study against Gleevec (imatinib) in an effort to move its product toward front-line use in CML, but due to an increasing side-effect profile, including serious arterial thrombotic events and cardiovascular toxicities, the FDA suspended the marketing of ponatinib in the U.S. That led to a significant decrease in shareholder value for the company.
Subsequently, the company worked with the FDA and was able to revise its label to a more restrictive patient population, getting the drug back on the market. Most investors look at the more restricted label and think a company with a market valuation of more than $1B and a restricted label is more than fairly valued. Given the lower peak revenue potential in the $100–150 million range ($100–150M), investors perceive Ariad as an overvalued stock trading at 10 times its peak revenue potential for Iclusig. But, in our opinion, this is where the opportunity lies.
"With existing branded products going generic over the next five years or so, pharmas need to license or acquire outright the products that biotech companies are developing."
What we believe investors are missing is that Ariad has an extremely active drug with ponatinib. We know that off-label sales are occurring in the second-line CML market right now, and as more physicians get comfortable with the side-effect profile, we believe the significant activity seen with ponatinib will help increase market share in other indications—even within CML. We believe Ariad is going to grow market share beyond the third-line and fourth-line CML market. In addition, the drug is being evaluated in several other solid tumor indications.
Ariad also has a pipeline of products, including a new anaplastic lymphoma kinase (ALK) inhibitor called AP26113, which reported outstanding data in advanced malignancies at ASCO. When you think ALK inhibitors, you probably think of the two major ones, Xalkori (crizotinib; Pfizer) or Novartis' Zykadia (ceritinib). A slew of other ALK inhibitors are in development, but AP26113 seems to have generated some differentiated data, which was presented at ASCO. The data differentiates AP26113 not just in its activity, which we believe is slightly better than Novartis' Zykadia, but we also believe the side effect profile is better. Ariad's pipeline sets the company up as one of the more interesting acquisition targets in the biotechnology space.
…
das komplette Interview gibts hier: www.thelifesciencesreport.com/pub/na/...-biotech-front-runners
…
TLSR: Could you mention another name?
RB: Sure. Ariad Pharmaceuticals Inc. (ARIA:NASDAQ) is a turnaround story as well. Last year the company ran into a significant snag. Ariad had the distinct pleasure of not only successfully getting Iclusig (ponatinib) approved in mid-December 2012, a full three months ahead of its Prescription Drug User Fee Act (PDUFA) date, but it also achieved regulatory approval both in the U.S. and in Europe for the drug. Iclusig was approved for third-line use in chronic myelogenous leukemia (CML). Ariad was running a head-to-head Phase 3 study against Gleevec (imatinib) in an effort to move its product toward front-line use in CML, but due to an increasing side-effect profile, including serious arterial thrombotic events and cardiovascular toxicities, the FDA suspended the marketing of ponatinib in the U.S. That led to a significant decrease in shareholder value for the company.
Subsequently, the company worked with the FDA and was able to revise its label to a more restrictive patient population, getting the drug back on the market. Most investors look at the more restricted label and think a company with a market valuation of more than $1B and a restricted label is more than fairly valued. Given the lower peak revenue potential in the $100–150 million range ($100–150M), investors perceive Ariad as an overvalued stock trading at 10 times its peak revenue potential for Iclusig. But, in our opinion, this is where the opportunity lies.
"With existing branded products going generic over the next five years or so, pharmas need to license or acquire outright the products that biotech companies are developing."
What we believe investors are missing is that Ariad has an extremely active drug with ponatinib. We know that off-label sales are occurring in the second-line CML market right now, and as more physicians get comfortable with the side-effect profile, we believe the significant activity seen with ponatinib will help increase market share in other indications—even within CML. We believe Ariad is going to grow market share beyond the third-line and fourth-line CML market. In addition, the drug is being evaluated in several other solid tumor indications.
Ariad also has a pipeline of products, including a new anaplastic lymphoma kinase (ALK) inhibitor called AP26113, which reported outstanding data in advanced malignancies at ASCO. When you think ALK inhibitors, you probably think of the two major ones, Xalkori (crizotinib; Pfizer) or Novartis' Zykadia (ceritinib). A slew of other ALK inhibitors are in development, but AP26113 seems to have generated some differentiated data, which was presented at ASCO. The data differentiates AP26113 not just in its activity, which we believe is slightly better than Novartis' Zykadia, but we also believe the side effect profile is better. Ariad's pipeline sets the company up as one of the more interesting acquisition targets in the biotechnology space.
…
das komplette Interview gibts hier: www.thelifesciencesreport.com/pub/na/...-biotech-front-runners
Es gibt keine neuen Beiträge.
|
Werbung
Passende Knock-Outs auf DAX
| Strategie | Hebel | |||
| Steigender DAX-Kurs | 5,00 | 10,00 | 15,00 | |
| Fallender DAX-Kurs | 5,00 | 10,00 | 15,00 | |
Den Basisprospekt sowie die Endgültigen Bedingungen finden Sie jeweils hier: DE000VG93X73
, DE000VK2CUW4
, DE000VH9H4E3
, DE000VH4ATM2
, DE000VJ0JNZ4
, DE000VG8DT04
.Bitte informieren Sie sich vor Erwerb ausführlich über Funktionsweise und Risiken. Bitte beachten Sie auch die weiteren Hinweise zu dieser Werbung.
Neueste Beiträge aus dem ARIAD Pharmaceuticals, Inc. Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 58 | ARIAD Pharmaceuticals Inc. | JoWu81 | Card60 | 25.04.21 01:33 | ||
3 | 46 | Ariad Pharmaceuticals Inc. A real hot stock! | FernandeZ | FernandeZ | 25.04.21 00:53 | |
| 18 | 4.875 | Ariad Pharmaceuticals - der letzte Thread | steven-bln | vstrecker | 25.04.21 00:38 | |
| 23 | 3.206 | Ariad Pharmaceuticals-Neu | Heron | Heron | 04.12.18 18:56 | |
| 36 | 9.311 | Ariad Pharma on the Top | MasterbrokerUSA | MasterbrokerUSA | 26.09.16 18:45 |